156 related articles for article (PubMed ID: 37204251)
1. G-protein-coupled receptor 141 mediates breast cancer proliferation and metastasis by regulating oncogenic mediators and the p-mTOR/p53 axis.
Parija M; Adhya AK; Mishra SK
Oncotarget; 2023 May; 14():466-480. PubMed ID: 37204251
[TBL] [Abstract][Full Text] [Related]
2. Metastatic role of mammalian target of rapamycin signaling activation by chemoradiotherapy in advanced rectal cancer.
Shiratori H; Kawai K; Okada M; Nozawa H; Hata K; Tanaka T; Nishikawa T; Shuno Y; Sasaki K; Kaneko M; Murono K; Emoto S; Ishii H; Sonoda H; Ushiku T; Ishihara S
Cancer Sci; 2020 Apr; 111(4):1291-1302. PubMed ID: 31997546
[TBL] [Abstract][Full Text] [Related]
3. Differentiated pre-adipocytes promote proliferation, migration and epithelial-mesenchymal transition in breast cancer cells of different p53 status.
Avşar Abdik E
Mol Biol Rep; 2021 Jun; 48(6):5187-5198. PubMed ID: 34213707
[TBL] [Abstract][Full Text] [Related]
4. Bisdemethoxycurcumin Promotes Apoptosis and Inhibits the Epithelial-Mesenchymal Transition through the Inhibition of the G-Protein-Coupled Receptor 161/Mammalian Target of Rapamycin Signaling Pathway in Triple Negative Breast Cancer Cells.
Chou CH; Wang HK; Lin YC; Tsai DH; Lu MT; Ho CT; Hseu YC; Yang HL; Way TD
J Agric Food Chem; 2021 Dec; 69(48):14557-14567. PubMed ID: 34813306
[TBL] [Abstract][Full Text] [Related]
5. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
[TBL] [Abstract][Full Text] [Related]
6. Distinctive role of SIK1 and SIK3 isoforms in aerobic glycolysis and cell growth of breast cancer through the regulation of p53 and mTOR signaling pathways.
Ponnusamy L; Manoharan R
Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118975. PubMed ID: 33545220
[TBL] [Abstract][Full Text] [Related]
7. MiR-15/16 complex targets p70S6 kinase 1 and controls cell proliferation in MDA-MB-231 breast cancer cells.
Janaki Ramaiah M; Lavanya A; Honarpisheh M; Zarea M; Bhadra U; Bhadra MP
Gene; 2014 Dec; 552(2):255-64. PubMed ID: 25261849
[TBL] [Abstract][Full Text] [Related]
8. BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition.
Niu W; Luo Y; Zhou Y; Li M; Wu C; Duan Y; Wang H; Fan S; Li Z; Xiong W; Li X; Li G; Ren C; Li H; Zhou M
J Exp Clin Cancer Res; 2020 Feb; 39(1):30. PubMed ID: 32028981
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
[TBL] [Abstract][Full Text] [Related]
10. Tumor-promoting properties of miR-8084 in breast cancer through enhancing proliferation, suppressing apoptosis and inducing epithelial-mesenchymal transition.
Gao Y; Ma H; Gao C; Lv Y; Chen X; Xu R; Sun M; Liu X; Lu X; Pei X; Li P
J Transl Med; 2018 Feb; 16(1):38. PubMed ID: 29471858
[TBL] [Abstract][Full Text] [Related]
11. Newly identified lncRNA-45 promotes breast cancer metastasis through activating the mTOR signaling pathway.
Qiu J; Guo Y; Wang S; Ren Q; Dong Z; Gao M; Ma J; Chen S; Liu S
Biochem Biophys Res Commun; 2023 Jan; 640():40-49. PubMed ID: 36502630
[TBL] [Abstract][Full Text] [Related]
12. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
[TBL] [Abstract][Full Text] [Related]
13. CircRNA_0005075 suppresses carcinogenesis via regulating miR-431/p53/epithelial-mesenchymal transition axis in gastric cancer.
Wu J; Chen Z; Song Y; Zhu Y; Dou G; Shen X; Zhou Y; Jiang H; Li J; Peng Y
Cell Biochem Funct; 2020 Oct; 38(7):932-942. PubMed ID: 32133664
[TBL] [Abstract][Full Text] [Related]
14. Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene.
Lam S; Wiercinska E; Teunisse AF; Lodder K; ten Dijke P; Jochemsen AG
Breast Cancer Res Treat; 2014 Nov; 148(1):7-18. PubMed ID: 25257729
[TBL] [Abstract][Full Text] [Related]
15. RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer.
Xue JQ; Xia TS; Liang XQ; Zhou W; Cheng L; Shi L; Wang Y; Ding Q
BMC Cancer; 2014 May; 14():322. PubMed ID: 24884756
[TBL] [Abstract][Full Text] [Related]
16. HERC5/IFI16/p53 signaling mediates breast cancer cell proliferation and migration.
Liu C; Li L; Hou G; Lu Y; Gao M; Zhang L
Life Sci; 2022 Aug; 303():120692. PubMed ID: 35671810
[TBL] [Abstract][Full Text] [Related]
17. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling.
Bhardwaj A; Ganesan N; Tachibana K; Rajapakshe K; Albarracin CT; Gunaratne PH; Coarfa C; Bedrosian I
PLoS One; 2015; 10(5):e0127678. PubMed ID: 26000884
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.
de Stephanis L; Mangolini A; Servello M; Harris PC; Dell'Atti L; Pinton P; Aguiari G
J Cell Physiol; 2018 Sep; 233(9):6911-6924. PubMed ID: 29323708
[TBL] [Abstract][Full Text] [Related]
19. MARK2 potentiate aerobic glycolysis-mediated cell growth in breast cancer through regulating mTOR/HIF-1α and p53 pathways.
Ponnusamy L; Natarajan SR; Manoharan R
J Cell Biochem; 2022 Apr; 123(4):759-771. PubMed ID: 35048405
[TBL] [Abstract][Full Text] [Related]
20. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
